Generic pharmaceutical company Hikma Pharmaceuticals plc (LSE:HIK) (NASDAQ Dubai:HIK) (OTC:HKMPY) reported on Thursday that its wholly owned US subsidiary Hikma Pharmaceuticals USA Inc has received approval from the US Food and Drug Administration (FDA) for its Icosapent Ethyl Capsules, 1 gm.
The drug is indicated to reduce the risk of heart attack, stroke and other types of heart problems.
Icosapent Ethyl Capsules are the generic equivalent to Vascepa, which is a registered trademark of Amarin Pharmaceuticals Ireland Limited.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa patents owned by Amarin. The District Court decision is currently being appealed.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream